Cwm LLC Acquires 277 Shares of Amedisys, Inc. (NASDAQ:AMED)

Cwm LLC lifted its holdings in shares of Amedisys, Inc. (NASDAQ:AMED) by 14.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,190 shares of the health services provider’s stock after acquiring an additional 277 shares during the period. Cwm LLC’s holdings in Amedisys were worth $211,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Banque Cantonale Vaudoise bought a new stake in shares of Amedisys during the first quarter worth about $60,000. Innealta Capital LLC bought a new stake in Amedisys in the 2nd quarter worth about $64,000. Covestor Ltd grew its position in Amedisys by 134.2% in the 1st quarter. Covestor Ltd now owns 780 shares of the health services provider’s stock worth $72,000 after purchasing an additional 447 shares in the last quarter. Signaturefd LLC grew its position in Amedisys by 88.2% in the 2nd quarter. Signaturefd LLC now owns 1,131 shares of the health services provider’s stock worth $104,000 after purchasing an additional 530 shares in the last quarter. Finally, GAM Holding AG bought a new stake in Amedisys in the 2nd quarter worth about $275,000. 94.36% of the stock is owned by institutional investors.

Amedisys Stock Performance

Amedisys stock opened at $97.05 on Wednesday. The firm’s 50 day simple moving average is $97.16 and its 200 day simple moving average is $95.43. The firm has a market capitalization of $3.17 billion, a PE ratio of -151.64, a price-to-earnings-growth ratio of 1.89 and a beta of 0.78. Amedisys, Inc. has a 1-year low of $89.55 and a 1-year high of $98.95. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 0.30.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Wednesday, July 24th. The health services provider reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.22 by $0.10. The firm had revenue of $591.19 million for the quarter, compared to analyst estimates of $579.34 million. Amedisys had a net margin of 4.02% and a return on equity of 12.39%. As a group, analysts expect that Amedisys, Inc. will post 4.66 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on AMED shares. William Blair downgraded shares of Amedisys from an “outperform” rating to a “market perform” rating in a research report on Monday, July 1st. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $101.00 price objective on shares of Amedisys in a research report on Thursday, July 25th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Amedisys from a “buy” rating to a “hold” rating and set a $101.00 price objective for the company. in a research report on Monday, July 29th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, Amedisys has a consensus rating of “Hold” and an average price target of $100.67.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.